arbutus
announces
mg
week
data
chronic
hepatitis
b
subjects
demonstrating
significant
continuous
reductions
hbsag
mean
hbsag
reduction
log
iu
ml
week
favorable
safety
tolerability
profile
warminster
globe
newswire
arbutus
biopharma
corporation
nasdaq
abus
biopharmaceutical
company
primarily
focused
developing
cure
people
chronic
hepatitis
b
virus
hbv
infection
well
therapies
treat
coronaviruses
including
today
reports
continued
positive
data
ongoing
phase
clinical
trial
proprietary
galnac
delivered
rnai
compound
new
data
demonstrate
chronic
hbv
subjects
single
subcutaneous
injection
mg
resulted
mean
hbsag
reduction
log
iu
ml
week
william
collier
president
chief
executive
officer
arbutus
stated
mg
data
coupled
previously
disclosed
mg
data
mean
two
doses
demonstrated
meaningful
reductions
hbsag
favorable
safety
tolerability
profile
currently
dosing
chronic
hbv
subjects
four
cohorts
using
mg
every
mg
every
doses
determine
optimal
dosing
regimen
believe
potentially
offer
people
chronic
hbv
low
dose
treatment
minimum
arbutus
expects
present
initial
results
ongoing
phase
clinical
trial
mg
cohorts
mg
cohort
hbv
dna
positive
subjects
well
follow
mg
cohorts
upcoming
scientific
meeting
later
year
addition
ongoing
mg
cohorts
subjects
dosed
company
also
initiated
mg
cohorts
subjects
dosed
intervals
mean
hbsag
changes
baseline
mg
cohort
b
mg
cohort
c
week
day
mean
iu
ml
standard
error
mean
gaston
picchio
chief
development
officer
arbutus
stated
mean
hbsag
decline
seen
mg
cohort
consistent
seen
prior
cohorts
importantly
data
demonstrate
consistent
efficacy
favorable
safety
profile
intermediate
dose
findings
support
continued
evaluation
mg
dose
portion
ongoing
clinical
summary
clinical
trial
design
ongoing
clinical
trial
consisting
three
parts
part
three
cohorts
healthy
subjects
randomized
receive
mg
mg
mg
placebo
part
hbeag
positive
negative
chronic
hbv
subjects
background
nucleos
ide
therapy
hbv
dna
limit
quantitation
received
mg
mg
additional
cohort
part
included
mg
hbv
dna
positive
chronic
hbv
subjects
part
chronic
hbv
subjects
hbv
dna
negative
first
hbv
dna
positive
later
receiving
six
months
rna
interference
rnai
therapeutic
targeted
hepatocytes
using
arbutus
novel
covalently
conjugated
galnac
delivery
technology
enables
subcutaneous
delivery
inhibits
viral
replication
reduces
hbv
antigens
including
hepatitis
b
surface
antigen
preclinical
models
reducing
hepatitis
b
surface
antigen
thought
key
prerequisite
enable
reawakening
patient
immune
system
respond
virus
ongoing
phase
clinical
trial
demonstrated
positive
safety
tolerability
data
meaningful
reductions
hepatitis
b
surface
antigen
hbv
chronic
hepatitis
b
virus
hbv
infection
debilitating
disease
liver
afflicts
million
people
worldwide
million
people
china
estimated
world
health
organization
hbv
global
epidemic
affects
people
hepatitis
c
virus
hcv
hiv
infection
higher
morbidity
mortality
rate
hbv
leading
cause
chronic
liver
disease
need
liver
transplantation
one
million
people
worldwide
die
every
year
causes
current
standard
care
patients
chronic
hbv
infection
suppressive
treatment
medications
reduce
eliminate
virus
resulting
low
cure
rates
significant
unmet
need
new
therapies
treat
hbv
arbutus
arbutus
biopharma
corporation
publicly
traded
nasdaq
abus
biopharmaceutical
company
dedicated
discovering
developing
commercializing
cure
people
chronic
hepatitis
b
virus
hbv
infection
company
advancing
multiple
drug
product
candidates
may
combined
potentially
curative
regimen
chronic
hbv
infection
arbutus
also
initiated
drug
discovery
development
effort
treating
coronaviruses
including
information
please
visit
december
outbreak
novel
strain
coronavirus
identified
wuhan
china
virus
continues
spread
globally
declared
pandemic
world
health
organization
spread
nearly
every
country
world
impact
pandemic
likely
continue
extensive
many
aspects
society
pandemic
resulted
likely
continue
result
significant
disruptions
businesses
number
countries
jurisdictions
around
world
implemented
extreme
measures
try
slow
spread
virus
measures
include
closing
businesses
requiring
people
stay
homes
latter
raises
uncertainty
regarding
ability
travel
hospitals
order
participate
clinical
trials
additional
measures
likely
continue
major
impact
clinical
development
least
include
shortages
delays
supply
chain
prohibitions
certain
countries
enrolling
subjects
new
clinical
trials
able
progress
clinical
activities
date
possible
predict
pandemic
negatively
impact
plans
timelines
future
statements
information
press
release
contains
statements
within
meaning
section
securities
act
section
securities
exchange
act
information
within
meaning
canadian
securities
laws
collectively
statements
statements
press
release
include
statements
arbutus
expectations
regarding
timing
clinical
development
product
candidates
potential
low
dose
treatment
hbv
minimum
injections
arbutus
expectation
present
mg
data
mg
data
hbv
dna
positive
subjects
well
follow
mg
cohorts
upcoming
scientific
meeting
later
year
arbutus
expectations
regarding
effect
pandemic
business
respect
statements
contained
press
release
arbutus
made
numerous
assumptions
regarding
among
things
effectiveness
timeliness
preclinical
studies
clinical
trials
usefulness
data
timeliness
regulatory
approvals
continued
demand
arbutus
assets
stability
economic
market
conditions
arbutus
considers
assumptions
reasonable
assumptions
inherently
subject
significant
business
economic
competitive
market
social
uncertainties
contingencies
including
uncertainties
contingencies
related
ongoing
pandemic
additionally
known
unknown
risk
factors
could
cause
arbutus
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
contained
herein
known
risk
factors
include
among
others
anticipated
studies
clinical
trials
may
costly
take
longer
complete
anticipated
may
never
initiated
completed
may
generate
results
warrant
future
development
tested
drug
candidate
arbutus
may
elect
change
strategy
regarding
product
candidates
clinical
development
activities
arbutus
may
receive
necessary
regulatory
approvals
clinical
development
arbutus
products
economic
market
conditions
may
worsen
market
shifts
may
require
change
strategic
focus
ongoing
pandemic
could
significantly
disrupt
arbutus
clinical
development
programs
complete
discussion
risks
uncertainties
facing
arbutus
appears
arbutus
annual
report
form
arbutus
quarterly
reports
form
arbutus
continuous
periodic
disclosure
filings
available
statements
herein
qualified
entirety
cautionary
statement
arbutus
disclaims
obligation
revise
update
statements
publicly
announce
result
revisions
statements
contained
herein
reflect
future
results
events
developments
except
required
law
contact
information
investors
media
william
collier
president
ceo
phone
email
ir
pam
murphy
investor
relations
consultant
phone
email
ir
